Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12026417 | 0.83 | HRH3 (0.34) | CYP2D6KCNH2HRH3LMNAGAA | |
| SCHEMBL24837394 | 0.78 | — | — | |
| SCHEMBL18627867 | 0.77 | HRH3 (0.33) | CYP2D6KCNH2HRH3LMNAGAA | |
| SCHEMBL21625313 | 0.77 | HRH3 (0.33) | CYP2D6KCNH2HRH3LMNAGAA | |
| SCHEMBL10254306 | 0.77 | PIK3CA (0.34) | CYP2D6KCNH2HRH3LMNAGAA | |
| SCHEMBL26400721 | 0.76 | CYP2D6 (0.46) | CYP2D6HRH3NAMPTALDH1A1 | |
| SCHEMBL26400792 | 0.76 | CYP2D6 (0.36) | CYP2D6HRH3 | |
| SCHEMBL19544965 | 0.76 | NCF1 (0.34) | CYP2D6GAAALDH1A1 | |
| SCHEMBL24261284 | 0.75 | PIK3CA (0.35) | PIK3CA | |
| SCHEMBL12206044 | 0.75 | PIK3CA (0.35) | PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | ENPP1, ENPP3, SMPD1 | CYP2D6 2442/4885KCNH2 4285/4885HRH3 4216/4885 |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | ENPP1, ENPP3, SMPD1 | CYP2D6 2442/4885KCNH2 4285/4885HRH3 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.